187 related articles for article (PubMed ID: 8988341)
21. Odanacatib for the treatment of osteoporosis.
Boggild MK; Gajic-Veljanoski O; McDonald-Blumer H; Ridout R; Tile L; Josse R; Cheung AM
Expert Opin Pharmacother; 2015; 16(11):1717-26. PubMed ID: 26149759
[TBL] [Abstract][Full Text] [Related]
22. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.
Hornby SB; Evans GP; Hornby SL; Pataki A; Glatt M; Green JR
Calcif Tissue Int; 2003 Apr; 72(4):519-27. PubMed ID: 12574877
[TBL] [Abstract][Full Text] [Related]
23. [Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate].
Miki T; Minamide T
Clin Calcium; 2007 Jan; 17(1):18-22. PubMed ID: 17211089
[TBL] [Abstract][Full Text] [Related]
24. Bisphosphonates: mechanisms of action and clinical use in osteoporosis--an update.
Fleisch H
Horm Metab Res; 1997 Mar; 29(3):145-50. PubMed ID: 9137986
[TBL] [Abstract][Full Text] [Related]
25. Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of strontium ranelate.
Marie PJ
Osteoporos Int; 2003; 14 Suppl 3():S9-12. PubMed ID: 12730801
[TBL] [Abstract][Full Text] [Related]
26. Effects of the bisphosphonate YM175 on bone mineral density, strength, structure, and turnover in ovariectomized beagles on concomitant dietary calcium restriction.
Motoie H; Nakamura T; O'uchi N; Nishikawa H; Kanoh H; Abe T; Kawashima H
J Bone Miner Res; 1995 Jun; 10(6):910-20. PubMed ID: 7572315
[TBL] [Abstract][Full Text] [Related]
27. Bisphosphonate therapy in children with secondary osteoporosis.
Papapoulos SE
Horm Res Paediatr; 2011; 76 Suppl 1():24-7. PubMed ID: 21778744
[TBL] [Abstract][Full Text] [Related]
28. [Fluoride treatment: a good choice in osteoporosis].
Duursma SA; Raymakers JA
Ned Tijdschr Geneeskd; 1998 Aug; 142(34):1915-9. PubMed ID: 9856178
[TBL] [Abstract][Full Text] [Related]
29. Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation.
Marie PJ
Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S11-5. PubMed ID: 16735840
[TBL] [Abstract][Full Text] [Related]
30. Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo.
van der Pluijm G; Binderup L; Bramm E; van der Wee-Pals L; De Groot H; Binderup E; Löwik C; Papapoulos S
J Bone Miner Res; 1992 Aug; 7(8):981-6. PubMed ID: 1442212
[TBL] [Abstract][Full Text] [Related]
31. Novel approaches to the treatment of osteoporosis.
Appelman-Dijkstra NM; Papapoulos SE
Best Pract Res Clin Endocrinol Metab; 2014 Dec; 28(6):843-57. PubMed ID: 25432356
[TBL] [Abstract][Full Text] [Related]
32. Is prolonged stimulation of bone growth a therapeutic possibility?
Mundy GR
Mol Cell Endocrinol; 1991 Feb; 75(2):C19-25. PubMed ID: 2050268
[No Abstract] [Full Text] [Related]
33. Present and future of osteoporosis therapy.
Seeman E; Tsalamandris C; Bass S; Pearce G
Bone; 1995 Aug; 17(2 Suppl):23S-29S. PubMed ID: 8579894
[TBL] [Abstract][Full Text] [Related]
34. [Inhibitors of HMG-CoA reductase in prevention of osteoporosis and bone fractures. Similar mechanism of action of statins and bisphosphonates].
Stajszczyk M; Mykała-Cieśla J
Pol Arch Med Wewn; 2002 Jan; 107(1):85-91. PubMed ID: 12046350
[No Abstract] [Full Text] [Related]
35. Alendronate increases skeletal mass of growing rats during unloading by inhibiting resorption of calcified cartilage.
Bikle DD; Morey-Holton ER; Doty SB; Currier PA; Tanner SJ; Halloran BP
J Bone Miner Res; 1994 Nov; 9(11):1777-87. PubMed ID: 7863829
[TBL] [Abstract][Full Text] [Related]
36. Long-term disuse osteoporosis seems less sensitive to bisphosphonate treatment than other osteoporosis.
Li CY; Price C; Delisser K; Nasser P; Laudier D; Clement M; Jepsen KJ; Schaffler MB
J Bone Miner Res; 2005 Jan; 20(1):117-24. PubMed ID: 15619677
[TBL] [Abstract][Full Text] [Related]
37. [Bone remodeling].
Lerner UH; Ljunggren O
Lakartidningen; 2006 Oct 4-10; 103(40):2972-5. PubMed ID: 17115661
[No Abstract] [Full Text] [Related]
38. Treatment with the combination of ibandronate plus eldecalcitol has a synergistic effect on inhibition of bone resorption without suppressing bone formation in ovariectomized rats.
Sakai S; Takeda S; Sugimoto M; Shimizu M; Shimonaka Y; Yogo K; Hashimoto J; Bauss F; Endo K
Bone; 2015 Dec; 81():449-458. PubMed ID: 26281770
[TBL] [Abstract][Full Text] [Related]
39. Bisphosphonates: pharmacology, mechanisms of action and clinical uses.
Russell RG; Croucher PI; Rogers MJ
Osteoporos Int; 1999; 9 Suppl 2():S66-80. PubMed ID: 10525729
[No Abstract] [Full Text] [Related]
40. Advantages of concurrent use of anabolic and antiresorptive agents over single use of these agents in increasing trabecular bone volume, connectivity, and biomechanical competence of rat vertebrae.
Kobayashi S; Shimizu T; Mehdi R; Nawata M; Kojima S; Tsutsumimoto T; Iorio R; Takaoka K
Bone; 1999 Dec; 25(6):703-12. PubMed ID: 10593416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
